Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as chief executive officer from 1 April 2025.

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

The team believes that the structure was in use until the 8th century BCE, the middle of the period when the Kings of Judah ruled. A scarab seal from the 8th century BCE uncovered during the ...

The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and datopotamab deruxtecan (Dato-DXd), a TROP2 directed ADC, which are being jointly developed and commercialized globally ...

Earth's inner core may actually have two distinct layers. (alexlmx/Canva Pro) "We found evidence that may indicate a change in the structure of iron, which suggests perhaps two separate cooling events ...

ApoB-100’s massive size and association with lipids in LDL have frustrated conventional approaches to studying its detailed structure. Berndsen and Cassidy and Reimund et al. have overcome this ...

Enhertu is already approved as a third-line therapy for HER2-positive metastatic breast cancer and a second-line therapy for HER2-positive metastatic gastric cancer, and recent data from the ...

AstraZeneca and Daiichi Sankyo’s Enhertu cancer drug has picked up a second indication, in patients who have stomach cancer and haven’t responded to Roche’s Herceptin (trastuzumab).